Nrx Pharmaceuticals Inc Stock Price, News & Analysis

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute in La Jolla, CA. Kadima, a profitable clinic specializing in interventional psychiatry, will serve as the clinical model for HOPE's nationwide treatment network. The institute is a leading research site for CNS and psychedelic therapies, offering treatments including ketamine, Spravato, and TMS for conditions like suicidal depression and PTSD.

Dr. David Feifel, Kadima's founder and a recognized expert in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer post-acquisition. The acquisition is expected to be accretive to revenue and EBITDA for both NRx and HOPE, subject to closing conditions and financing finalization.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has scheduled its first quarter 2025 financial results announcement for May 15, 2025, after market close. The company will release results through a press release available on their investor relations website, followed by a conference call at 4:30 PM ET.

Interested parties can access the conference call via webcast on the company's website or by telephone using the following dial-in numbers: +1-800-717-1738 (domestic) or +1-646-307-1865 (international).

NRx Pharmaceuticals (NASDAQ:NRXP) and its subsidiary HOPE Therapeutics announced an upcoming investor event at Mar-A-Lago Club on May 8, 2025. The event will discuss strategic initiatives including HOPE's interventional psychiatry clinic expansion and NRx's clinical pipeline progress.

Key discussion topics include: HOPE's recent clinic acquisitions, integration of digital health solutions, status of NRX-100 (preservative-free IV Ketamine) NDA following a $4.3M FDA filing fee waiver, a new patent filing for NRX-100 that could provide market exclusivity until 2045, and the Breakthrough Therapy Designation of NRX-101 for bipolar depression treatment. Dr. Jonathan Javitt, Chairman and CEO of NRx and Co-CEO of HOPE Therapeutics, will lead the discussion.

NRx Pharmaceuticals (NASDAQ:NRXP) has filed a patent application for NRX-100, its preservative-free intravenous ketamine formulation designed to treat suicidal depression. The patent, if granted, would provide exclusivity until 2045 and could be listed in the FDA Orange Book. NRX-100's key innovation is its formulation without benzethonium chloride or other preservatives, which have been linked to cytotoxic or neurotoxic effects.

The company has already initiated an NDA filing for NRX-100 and received Fast Track Designation with NRX-101 from the FDA. With a recent FDA fee waiver in place, NRx plans to complete its NDA submission in the current quarter. The patent application includes twenty claims covering pharmaceutical compositions, treatment methods, and manufacturing processes.

NRx Pharmaceuticals (NASDAQ: NRXP) has received an FDA waiver for the $4.3 million filing fee for its New Drug Application for NRX-100, a preservative-free ketamine treatment for suicidal depression. The company plans to complete the NDA filing by Q2 2025.

The drug's key innovation is its preservative-free formulation, avoiding benzethonium chloride, which has potential neurotoxic effects. NRX-100 has demonstrated two-year shelf life stability and could receive long-term exclusivity upon FDA approval.

Clinical trials have shown ketamine's superiority over placebo and active comparators in treating depression and suicidal ideation. The FDA's fee waiver, granted to Small Business Entities and drugs deemed necessary for Public Health, enables NRx to proceed with its application using existing resources. The company aims to make this potentially life-saving therapy accessible through insurance coverage, as current ketamine treatments for depression are not FDA-approved and require out-of-pocket payment.

NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, along with its wholly-owned subsidiary HOPE Therapeutics, announced their participation in an upcoming H.C. Wainwright @ Home fireside discussion.

The event is scheduled for Tuesday, April 22, 2025, at 10:00 AM EDT. Dr. Jonathan Javitt, who serves as both the Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, will engage in a fireside chat led by HCW Senior Biotech Analyst Vernon Bernardino.

Interested investors can access the webcast through the company's investor relations website at ir.nrxpharma.com/events or by contacting their HC Wainwright representative for registration.

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has signed a non-binding term sheet with a global medical device manufacturer for a strategic investment. The deal involves a $2.5 million investment to purchase Series A Convertible Preferred Stock at a $50 million pre-money valuation.

The investment terms include a dividend based on market conditions and the right to appoint a director to HOPE's Board. The pre-money valuation may be adjusted based on EBITDA results for Q3 2026. The funding, combined with expected bank financing and current assets, will support HOPE's recently announced clinic acquisitions.

HOPE Therapeutics aims to establish a network of clinics specializing in treating suicidal depression and PTSD using ketamine, TMS, and other treatment modalities.

HOPE Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has signed a definitive agreement to acquire Dura Medical, a revenue-generating and EBITDA-positive interventional psychiatry clinic on Florida's west coast. This acquisition, combined with the previously announced Neurospa TMS network, will expand HOPE's comprehensive mental health services in Florida.

Dura Medical, founded in 2018, specializes in treating mental health and chronic pain using advanced interventional psychiatry procedures, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), Spravato®, and Stellate Ganglion Blocks. The clinic serves both civilian and veteran patients through the Veterans Affairs Community Cares Network.

Stephen Durand, Dura's founder and a US Army Reserve Veteran, will serve as Director of Florida Clinic Operations for HOPE. Dura Medical aims to treat more than 10,000 people by 2026. The acquisition's closing is pending financial audits, regulatory approvals, and standard closing conditions.

NRx Pharmaceuticals (NASDAQ:NRXP) announced that its wholly-owned subsidiary, HOPE Therapeutics, has signed a binding Letter of Intent to acquire a majority stake in Neurospa TMS Holdings, which operates six interventional psychiatry clinics on Florida's Gulf Coast.

Neurospa, which is currently revenue-generating and EBITDA positive, provides comprehensive psychiatric care including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Spravato® treatments, along with traditional psychiatry and talk therapy. These services target patients with depression, suicidality, PTSD, anxiety, and related disorders.

The acquisition is expected to be accretive to HOPE's revenue projections for 2025. The deal completion is contingent on financial audits, definitive agreements, and standard closing conditions.